Clostridium perfringens Type C toxoid (C. perfringens Type C toxoid)

Clostridium perfringens Type C toxoid is an inactivated form of the potent exotoxins produced by Type C strains of the bacterium, primarily the Beta toxin (CPB) [2, 3]. The Beta toxin is a highly lethal, pore-forming protein that targets endothelial cells and is the primary virulence factor responsible for necrotizing enteritis and enterotoxemia in both humans and livestock [2, 6]. In its toxoid form, the toxin is chemically or thermally treated to eliminate its harmful enzymatic and cytotoxic activities while preserving its immunogenic properties [8, 11]. When used in vaccines, the toxoid induces the production of protective antibodies that neutralize the active toxin during subsequent exposure or infection [11, 17]. This immunological approach is critical for preventing devastating diseases such as 'pig-bel' in humans and fatal hemorrhagic enteritis in neonatal animals [1, 10]. The toxoid is a cornerstone of veterinary preventative medicine and has historically been used in human public health initiatives in high-risk regions [8, 16]. The native toxin's mechanism involves binding to the CD31 (PECAM-1) receptor on host cells, leading to pore formation and cell death [5, 12]. Neutralizing antibodies elicited by the toxoid prevent this binding, thereby protecting the host from the toxin's lethal effects [15].

Other names

Beta toxoidAlpha toxoidClostridium perfringens beta toxin (inactivated)C. perfringens Type C antigen

The toxoid acts as an immunogen that stimulates the production of neutralizing antibodies (antitoxins) against the native Clostridium perfringens Beta toxin [11]. These antibodies bind to the toxin's receptor-binding or pore-forming domains, preventing its interaction with host cell receptors like CD31 (PECAM-1) and subsequent membrane disruption [5, 15].